This week, we're thrilled to shine our leadership spotlight on Madhuri Borde, Executive Director of Market Intelligence and Alliance Management at Capsida Biotherapeutics. She draws inspiration from Capsida's commitment to making a meaningful impact on serious diseases through groundbreaking science. The dynamic nature of her work allows her to collaborate closely with leadership and scientists, tackling a variety of projects that keep each day fresh and engaging. Thank you, Madhuri, for your unwavering commitment to collaboration and innovation in our pursuit to unlock the potential of gene therapy for all! #LeadershipSpotlight #CapsidaBiotherapeutics #LifeChangingScience
Capsida Biotherapeutics
Biotechnology
Newbury Park, CA 13,439 followers
Engineering novel AAVs and developing the next generation of gene therapies
About us
Capsida Biotherapeutics Inc. is an industry-leading gene therapy platform company creating a new class of targeted, non-invasive gene therapies for patients with debilitating and life-threatening genetic disorders. Capsida's technology allows for the targeted penetration of cells and organs, while limiting collateral impact on non-targeted cells and organs, especially the liver. This technology allows for the delivery of the gene therapy in a non-invasive way through intravenous administration. Capsida's technology is protected by a growing intellectual property portfolio which includes more than 30 patent applications and one issued U.S. patent 11,149,256. The company is exploring using the technology across a broad range of life-threatening genetic disorders. Its initial pipeline consists of multiple neurologic disease programs. The company has strategic collaborations with AbbVie and CRISPR, which provide independent validation of Capsida's technology and capabilities. Capsida is a multi-functional and fully integrated biotechnology company with proprietary adeno-associated virus (AAV) engineering, multi-modality cargo development and optimization, translational biology, process development and state-of-the-art manufacturing, and broad clinical development experience. Capsida's biologically driven, high-throughput AAV engineering and cargo optimization platform originated from groundbreaking research in the laboratory of Viviana Gradinaru, Ph.D., a neuroscience professor at the California Institute of Technology.
- Website
-
http://www.capsida.com
External link for Capsida Biotherapeutics
- Industry
- Biotechnology
- Company size
- 51-200 employees
- Headquarters
- Newbury Park, CA
- Type
- Privately Held
- Founded
- 2019
- Specialties
- Biotechnology, AAV Engineering, Gene Therapy, Biopharmaceuticals, Protein Engineering, Analytical Development, Process Development, and AAV Immunology
Locations
-
Primary
1290 Rancho Conejo Blvd
Newbury Park, CA 91320, US
Employees at Capsida Biotherapeutics
Updates
-
We are proud to announce that two of our distinguished leadership team, Bethany Mancilla, our Chief Business Officer, and Rob Murphy, our Chief Manufacturing and Quality Officer, have been recognized as leaders in healthcare innovation. Their contributions to advancing gene therapy and addressing unmet medical needs have made a significant impact on both the industry and the community. This recognition highlights their dedication to pioneering innovative solutions and their commitment to improving patient outcomes. Congratulations to Bethany and Rob for being featured among the Valley's top health leaders! #CapsidaBiotherapeutics #HealthcareInnovation #GeneTherapy #Leadership
-
Our Capsida colleague Dr. Kimberly McDowell spoke at the inaugural GBA1 meeting this past June. Her presentation highlighted data on our candidate for Parkinson’s disease associated with GBA mutations. Our therapy is anticipated to enter the clinic in 1H 2025. You can now watch Dr. McDowell's presentation on YouTube: https://lnkd.in/gxj3hKKm The GBA1 meeting is organized by GBA1 Canada (G-Can) and sponsored by The Hilary and Galen Weston Foundation, the Silverstein Foundation, the J. Sebastian van Berkom and Ghislaine Saucier Foundation, Cure Parkinson’s, Parkinson’s Foundation, and The Michael J. Fox Foundation, along with other dedicated sponsors. #GeneTherapy #Neurodegeneration #GBA1 #ParkinsonsDisease #CapsidaBiotherapeutics
-
At Capsida, we are dedicated to unlocking the potential of gene therapy for all by developing next generation treatments using our breakthrough adeno-associated virus (AAV) engineered capsids. Our lead programs are in IND enabling studies for genetic epilepsy linked to STXBP1 mutations and Parkinson’s disease associated with GBA mutations. To learn more, visit our website at: https://capsida.com #GeneTherapyInnovation #CapsidaBiotherapeutics #BioPharma
-
A huge thank you to everyone who supported our team earlier this month #Move4PD and helped us raise awareness and funds for the Parkinson's Foundation. Let’s keep moving forward! #ParkinsonsAwareness #CommunitySupport
-
We were thrilled to present on our progress at #CGMesa24 earlier this week. We shared new preclinical data from our gene therapy program for Parkinson’s associated with GBA mutations, showing groundbreaking GCase expression and activity in non-human primates. We are also excited to continue to advance our IND enabling studies for genetic epilepsy caused by STXBP1 mutations. Both programs are well on track for IND filing in the first half of next year. #GeneTherapy #CapsidaBiotherapeutics
-
We’re excited to join other #cellandgenetherapy sector leaders at the Alliance for Regenerative Medicine Cell & Gene Meeting on the Mesa. Please join our CEO @Peter Anastasiou today at 3.45pm local time in the FLW Ballroom G. Recordings of the content from the meeting will be available for registrants via the website: https://lnkd.in/eiUpMy4 #CGMesa24 #GeneTherapy
-
#NEWS: At #SfN2024 we presented new preclinical data on CAP-003, our investigational gene therapy for Parkinson’s disease associated with GBA mutations (PD-GBA). Highlights: 🔎 Across doses and brain regions, including the substantia nigra, levels of GCase activity were increased by up to ~250% compared to untreated animals following CAP-003 IV infusion. Increases of 30% are expected to normalize GCase activity in patients with PD-GBA. 🔎 CAP-003 demonstrated brainwide RNA expression greater than 200-fold higher than IV-delivered AAV9, with significant detargeting of liver and DRGs. We are on track to file an IND in the first half of 2025. We will also present these data as part of a corporate presentation at the Cell & Gene Meeting on the Mesa in Phoenix, Arizona, on Tuesday, October 8, 2024, at 3:45 PM local time. Read the press release for full details: https://lnkd.in/gGP84sr4 #GeneTherapy #Biotech #Healthcare #SfN24 #CGMesa24
-
We look forward to presenting at the Society for Neuroscience (SfN) meeting in Chicago. Join us at our poster to learn more about our unprecedented, late breaking, preclinical data from our wholly owned gene therapy program for Parkinson’s Disease associated with GBA mutations. We are on track to file our IND in 1H 2025. Poster title: LBA003.86 / LBA84 - Systemic AAV gene therapy with CNS-targeted engineered capsids achieves significant GCase activity increases in the primate brain to support the potential treatment of PD-GBA Sunday, October 6, 2024, 2-3 PM ET MCP Hall A #SfN2024
-
The Cell & Gene Meeting on the Mesa is right around the corner! Organized by the Alliance for Regenerative Medicine, the event will host industry experts, including our CEO Peter Anastasiou His presentation will be on October 8 at 3:45pm local time. We’re thrilled to be part of one of our sector’s most important conferences aimed at advancing cell and gene therapy research and development. For a glimpse of our progress so far, watch below 👇 #CGMesa24